Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib in advanced renal cell carcinoma after TKI failure
CTR20150331Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in clear cell renal cell carcinoma (ccRCC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2015; status: active.
02
Drugs
anlotinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on CTR20150331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150331.